Live Analyst Rating Changes 1941 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/David Li
BofA
David Li
Bank of America Securities
Wall Street Analyst
★★☆☆☆
#2159
on 13Foresight · ranked by our own returns
0%
Success Rate
-39.9%
Average Return
0 of 4 calls profitable · -65.8% vs benchmark
📈 Across the calls we could measure, roughly 0% of David Li's ratings turned a profit when each position was held for 1 year — averaging -39.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

5 Buy 5 Hold 0 Sell
David's Stock Coverage 15 ratings · 2026-06-23
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
ZLAB
Zai Lab
 May 21, 2026 HOLD Strong Buy
+221.3% avg upside
13 analysts
$21.60
18.96% Upside
 -10.6%
HK:6160
BeOne Medicines Ltd
 May 21, 2026 BUY Strong Buy
+49.2% avg upside
2 analysts
$243.80
51.20% Upside
 ·
ONC
BeOne Medicines
 Nov 07, 2025 BUY Strong Buy
+27.8% avg upside
28 analysts
$402.20
48.59% Upside
 -15.6%
HK:3347
Hangzhou Tigermed Consulting Co., Ltd. Class H
 Aug 29, 2025 BUY Strong Buy
+71.5% avg upside
2 analysts
$56.00
76.90% Upside
 ·
HK:2607
Shanghai Pharmaceuticals Holding Co
 Jan 03, 2025 BUY Sell
+23.1% avg upside
2 analysts
$15.70
32.68% Upside
 ·
HK:1801
Innovent Biologics
 Jan 03, 2025 BUY Strong Buy
+33.5% avg upside
7 analysts
$56.90
24.56% Downside
 ·
HK:3692
Hansoh Pharmaceutical Group Company Limited
 Jun 07, 2024 BUY Strong Buy
+33.0% avg upside
5 analysts
$20.80
29.62% Downside
 ·
BNR
Burning Rock Biotech
 Sep 01, 2023 BUY Strong Buy
+909.8% avg upside
1 analyst
$73.00
909.76% Upside
 -61.4%
NBP
NovaBridge Biosciences
 Aug 31, 2022 BUY Strong Buy
+1289.1% avg upside
14 analysts
$64.60
4178.07% Upside
 ·
HK:1530
3SBio
 Dec 29, 2020 BUY Buy
+57.8% avg upside
3 analysts
$11.87
26.32% Downside
 ·
HK:1833
Ping An Healthcare and Technology Company
 Jul 30, 2020 BUY Buy
+216.4% avg upside
3 analysts
 — ·
HK:1093
CSPC Pharmaceutical Group
 Jul 30, 2020 BUY Strong Buy
+62.5% avg upside
6 analysts
 — ·
HK:1177
Sino Biopharmaceutical
 Jul 30, 2020 BUY Strong Buy
+78.5% avg upside
6 analysts
 — ·
YZCAY
Yankuang Energy Group Company Sponsored ADR Class H
 Apr 03, 2020 SELL Strong Sell
-96.1% avg upside
1 analyst
$0.65
96.06% Downside
 -72.2%
HK:2552
Hua Medicine
 Jun 13, 2019 BUY Strong Buy
+394.6% avg upside
1 analyst
$10.34
394.65% Upside
 ·
🔒 10 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
David Li — Frequently Asked Questions
How accurate are David Li's stock ratings?
Based on the calls 13Foresight could measure, about 0% of David's ratings were profitable over a one-year hold, with an average return of -39.9% per rating, or -65.8% versus the S&P 500. We score every analyst the same way, from historical prices.
How is David ranked on 13Foresight?
David Li is currently ranked #2159 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does David cover?
David most recently has ratings on ZLAB, HK:6160, ONC, HK:3347, HK:2607, HK:1801, HK:3692, BNR, NBP, HK:1530, HK:1833, HK:1093 and 3 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.